RFRu Feng

Ru Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ru Feng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Chang Li

    Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine

    1 shared publication
  • Chunli Zhang

    Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China

    1 shared publication
  • Fei Xiao

    Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

    1 shared publication
  • Gaoyuan Sun

    Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing China

    1 shared publication
  • Lili Zhang

    Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing China

    1 shared publication
  • Ye Liu

    The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission Beijing China

    1 shared publication

Latest Publications

  • Open Access

    mRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid Leukemia

    by Ziwei Chen, Yingyu Guo, Zaifeng Zhang, Chang Li, Lili Zhang, Ye Liu, Gaoyuan Sun, Fei Xiao, Ru Feng, Chunli Zhang

    The DNA demethylating therapy with azacitidine (AZA) is a promising therapeutic strategy for elderly patients with acute myeloid leukemia (AML). AZA primarily inhibits DNA methylation, promotes cell differentiation and apoptosis in AML. However, as a cytosine nucleoside analog, AZA also has the potential to be incorporated into RNA molecules. To assess the impact of AZA on RNA m5C methylation during demethylating therapy, we conducted Nanopore direct‐RNA sequencing on samples from three AML patients pre and after demethylating therapy, as well as on HL‐60 cells pretreated with AZA. We performed an integrated analysis of the transcriptome and the m5C methylome, contrasting the states of complete remission with those of active disease (AML). Our results revealed an extensive demethylation effect at the RNA level attributable to AZA and found that mRNA m5C modification may play a pivotal role in the progression of AML. Additionally, S100P was identified as a biomarker with significant prognostic implications. We also conducted a conjoint analysis of the transcriptome and the m5C methylome of the full‐length transcripts, uncovering several dysregulated mRNA isoforms. Collectively, our findings indicate that mRNA m5C methylation is implicated during AML progression, and AZA exhibits an overall suppressive effect on this process.